On February 25, 2015, the Board of Directors of Argos Therapeutics, Inc. appointed Philippe van Holle as a member of the audit committee of the Board, effective immediately. Mr. van Holle will replace Brian Underdown on the Audit Committee. Mr. Underdown will continue to serve as the chairman of the compensation committee of the Board and as a member of the nominating and governance committee of the Board.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% | -6.22% | +78.50% |
2019 | Argos Therapeutics, Inc. Went Out of Business | CI |
2019 | First Amended Liquidation Plan Approved for Argos Therapeutics, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
+78.50% | 567K | |
-1.62% | 89.22B | |
+1.32% | 40.49B | |
-15.73% | 32.79B | |
+64.13% | 26.23B | |
-21.28% | 14.52B | |
-8.50% | 13.09B | |
-44.07% | 11.6B | |
-13.06% | 11.5B | |
+4.94% | 8.82B |
- Stock Market
- Equities
- ARGSQ Stock
- News Argos Therapeutics, Inc.
- Argos Therapeutics, Inc. Announces Audit Committee Changes